A Systematic Review of the Treat and Extend Treatment Regimen with Anti-VEGF Agents for Neovascular Age-Related Macular Degeneration

被引：42
作者：
Gemenetzi M. [1 ]
Patel P.J. [1 ,2 ]
机构：
[1] NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust, London
[2] UCL Institute of Ophthalmology, London
来源：
Ophthalmology and Therapy | 2017年 / 6卷 / 1期
关键词：
Age-related macular degeneration; Anti-vascular endothelial growth factor intravitreal injections; Systematic review;
D O I：
10.1007/s40123-017-0087-5
中图分类号：
学科分类号：
摘要：
Despite significant progress in retaining vision for neovascular age-related macular degeneration patients in the era of treatment with intravitreal anti-VEGF agents, there is no universally accepted treatment regimen that defines the frequency of treatment needed to achieve the optimal visual outcomes while simultaneously balancing the burden of long-term, frequent and high-cost treatment. Treat and extend has recently and consistently been used by retina specialists to minimise the financial and psychological costs of the need for frequent treatment with anti-VEGF injections. This is a systematic review that presents evidence from clinical trials and the real world on the utilisation of treat and extend with anti-VEGF intravitreal injections in neovascular age-related macular degeneration, and discusses the experience gained thus far from the utilisation of such regimens to preserve vision when treating patients over the long-term. © 2017, The Author(s).
引用
收藏
页码：79 / 92
页数：13
相关论文
共 39 条
  • [1] Abraham P., Yue H., Wilson L., Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular agerelated macular degeneration: PIER study year 2, Am J Ophthalmol, 150, pp. 315-324, (2010)
  • [2] Schmidt-Erfurth U., Eldem B., Guymer R., Et al., Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE Study, Ophthalmology, 118, pp. 831-839, (2011)
  • [3] Holz F.G., Amoaku W., Donate J., Guymer R.H., Kellner U., Schlingermann R.O., Et al., Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study, Ophthalmology, 118, 4, pp. 663-671, (2011)
  • [4] Heier J.S., Antoszyk A.N., Pavan P.R., Et al., Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study, Ophthalmology, 113, 642, pp. e1-e4, (2006)
  • [5] Rosenfeld P.J., Heier J.S., Hantsbarger G., Et al., Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration, Ophthalmology, 113, 632, (2006)
  • [6] Fung A.E., Lalwani G.A., Rosenfeld P.J., Et al., An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration, Am J Ophthalmol, 143, pp. 566-583, (2007)
  • [7] Lalwani G.A., Rosenfeld P.J., Fung A.E., Et al., A variable-dosing regimen with intravitreal ranibizumab for neovascular agerelated macular degeneration: year 2 of the PrONTO study, Am J Ophthalmol, 148, pp. 43-58, (2009)
  • [8] Brown D.M., Michels M., Kaiser P.K., Et al., Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study, Ophthalmology, 116, pp. 57-65, (2009)
  • [9] Rosenfeld P.J., Brown D.M., Heier J.S., Et al., Ranibizumab for neovascular age-related macular degeneration, N Engl J Med, 355, pp. 1419-1431, (2006)
  • [10] Martin D.F., Maguire M.G., Et al., Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results, Ophthalmology, 119, 7, pp. 1388-1398, (2012)
1234